Compare SNBR & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SNBR | FHTX |
|---|---|---|
| Founded | 1987 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 186.9M | 247.1M |
| IPO Year | 1998 | 2020 |
| Metric | SNBR | FHTX |
|---|---|---|
| Price | $8.54 | $5.03 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $8.00 | ★ $11.50 |
| AVG Volume (30 Days) | ★ 868.4K | 158.2K |
| Earning Date | 11-05-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,440,882,000.00 | $24,518,000.00 |
| Revenue This Year | N/A | $47.50 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.49 | $2.95 |
| 52 Week High | $20.00 | $6.79 |
| Indicator | SNBR | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | 72.30 | 63.06 |
| Support Level | $7.63 | $4.21 |
| Resistance Level | $8.65 | $4.59 |
| Average True Range (ATR) | 0.76 | 0.29 |
| MACD | 0.22 | 0.03 |
| Stochastic Oscillator | 89.45 | 78.50 |
Sleep Number Corp. is a wellness technology company engaged in the design, manufacturing, marketing and distribution of sleep solutions. The Company generates revenue by marketing and selling its smart beds directly to new and existing customers through its vertically integrated, exclusive, direct-to-consumer retail touch points including Stores, Online, Phone, and Chat (Total Retail). The products offered by the company are Mattresses, Bedding, Pillows and Furniture.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.